TICKERNERD
Menu
ANNXANNXHealthcare · Biotechnology

ANNX Stock Forecast: Annexon, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$5.41
−3.39% on the day

The 10 Wall Street analysts covering Annexon, Inc. hold a median 12-month price target of $11 — +103.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 8 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$886.4M
Ticker Nerd rank
39 / 100
Median analyst target
$11
Analysts covering
10
Total return, dividends reinvested
1W
+6.2%
1M
−15.9%
YTD
+7.8%
1Y
+128.3%
From 52W high
−22.3%
From 52W low
+163.9%
$2.05
$6.96
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANNX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Annexon, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Aug 2026
39 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
73
Accruals
70
Volatility
49
Revisions
48
Size
47
Value
45
Issuance
43
Growth
32
Quality
23

Momentum (73): The shares have been drifting up relative to others.

Quality (23): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

The rank is the raw material. Whether the rules would actually own Annexon, Inc. — and when they’d sell — is the membership.

Wall Street

ANNX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANNX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00Oct 25Jan 26Apr 26Jul 26ANNXHigh $27Median $11Low $3

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
8 Buy1 Hold1 Sell
Low $3Median $11High $27

The green dot is the last close — the median target sits +103.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 July 2026CitizensInitiatesMarket Underperform$3.00
15 July 2026NeedhamMaintainsBuy$11 → $25
12 May 2026Goldman SachsInitiatesNeutral—
20 Mar 2026Chardan CapitalMaintainsBuy—
23 Dec 2025Chardan CapitalInitiatesBuy—
2 Dec 2025Clear StreetInitiatesBuy—
19 Nov 2025Wells FargoMaintainsOverweight—
15 Aug 2025HC Wainwright & Co.ReiteratesBuy—
14 May 2025HC Wainwright & Co.MaintainsBuy—
13 May 2025NeedhamMaintainsBuy—
4 Mar 2025NeedhamReiteratesBuy—
17 Dec 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024Cantor FitzgeraldReiteratesOverweight—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024NeedhamReiteratesBuy—
9 Sept 2024Cantor FitzgeraldReiteratesOverweight—
13 Aug 2024HC Wainwright & Co.ReiteratesBuy—
13 Aug 2024NeedhamReiteratesBuy—
5 June 2024Cantor FitzgeraldReiteratesOverweight—
4 June 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ANNX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Annexon, Inc. (ANNX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.0×

Cheaper than 88% of US stocks

Price / sales
—
Price / book
4.3×

Cheaper than 26% of US stocks

EV / EBITDA
−3.4×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−87.6%

Higher than 15% of US stocks

Return on assets
−45.3%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ANNX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANNXAnnexon, Inc.$886.4M
39
ACRSAclaris Therapeutics, Inc.$869.9M
67
DSGNDesign Therapeutics, Inc.$862.8M
64
TBPHTheravance Biopharma, Inc.$852.6M
100
KURAKura Oncology, Inc.$849.5M
68
SGPSpyGlass Pharma, Inc.$843.3M
1
SLDBSolid Biosciences, Inc.$899.6M
36
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANNX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ANNX news & analysis

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

GlobeNewsWire · 6 Aug 2026positive

Annexon reported that the first U.S. and European patient cohort of the GBS FORWARD study showed rapid, positive clinical responses in all tanruprubart-treated patients within one week. The company said the early outcomes reinforce the consistency and reproducibility of the treatment effect previously demonstrated in Phase 3 and real-world evidence studies.

Why it matters — An ANNX watcher would care because this cohort data supports the consistency and reproducibility of tanruprubart's clinical effect in GBS across further study settings.

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

GlobeNewsWire · 30 July 2026positive

Annexon announced it has secured a strategic credit facility for up to $200 million from Oxford Finance, aimed at expanding the company's financial capacity as its vonaprument and tanruprubart programs move toward registration.

Why it matters — The credit facility strengthens Annexon's financial position at a critical time when its lead programs are approaching potential regulatory milestones.

FAQ

Frequently asked questions about ANNX stock

What is the ANNX stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Annexon, Inc. have a median 12-month price target of $11, with estimates ranging from $3 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANNX stock a buy right now?

Of the 10 analysts covering Annexon, Inc., 8 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Annexon, Inc. 39 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANNX?

As at 8 Aug 2026, Annexon, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (73 of 100).

Will ANNX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +103.3% from the last close, and Ticker Nerd's factor model ranks Annexon, Inc. 39 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANNX stock forecast for 2030?

No analyst covering Annexon, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $27 over the next 12 months.

How has ANNX stock performed over the past year?

Annexon, Inc. returned +128.3% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Annexon, Inc. do?

Annexon, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for autoimmune, neurodegenerative, and ophthalmic diseases.

What is the latest news on ANNX?

The most recent item we track (GlobeNewsWire, 6 Aug 2026): "Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week". Annexon reported that the first U.S. and European patient cohort of the GBS FORWARD study showed rapid, positive clinical responses in all tanruprubart-treated patients within one week. The company said the early outcomes reinforce the consistency and reproducibility of the treatment effect previously demonstrated in Phase 3 and real-world evidence studies.

Company

About Annexon, Inc.

Annexon, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for autoimmune, neurodegenerative, and ophthalmic diseases. The company advances a pipeline of product candidates designed to target the classical complement pathway, a key component of the immune system implicated in these debilitating conditions. Its lead programs address unmet needs in areas such as Guillain-Barré syndrome, Huntington's disease, and geographic atrophy associated with age-related macular degeneration. Annexon, Inc. emphasizes innovative monoclonal antibodies that modulate complement activity to halt disease progression and preserve neurological and retinal function. Operating within the biotechnology industry of the healthcare sector, the company conducts clinical trials to evaluate the safety, efficacy, and potential of its therapies in patient populations. Founded in 2011 and headquartered in Brisbane, California, Annexon, Inc. plays a role in advancing treatments for complement-mediated disorders through rigorous scientific research and development efforts.

CEO Mr. Douglas E. Love Esq., J.D. · 93 employees · United States · https://www.annexonbio.com